<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074995</url>
  </required_header>
  <id_info>
    <org_study_id>CBVS857X2201</org_study_id>
    <nct_id>NCT02074995</nct_id>
  </id_info>
  <brief_title>Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects</brief_title>
  <official_title>Multiple Ascending, Sequential, Placebo-controlled, Double-blind Study to Assess Safety, Tolerability and Efficacy of BVS857 in Severe Burn Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15
      weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No formal analysis was performed as study was terminated due to low enrollment issues. (n=1
      patient was enrolled)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was prematurely terminated due to recruitment issues
  </why_stopped>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Over 1 year</time_frame>
    <description>Number of patients with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Measure by Change in Lean Body Mass (LBM)</measure>
    <time_frame>Groups 2,3&amp;4: Baseline, Day 35, Day 85 and Day 106</time_frame>
    <description>Total LBM is measured by dual energy X-ray absorptiometry (DXA) scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Cmax; The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Tmax; The Time to Reach the Maximum Concentration After Drug Administration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: AUClast; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: AUCinf; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to Infinity</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: T1/2; The Terminal Elimination Half-life</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:ay D1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: CL; The Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Intravenous Administration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Vz; The Volume of Distribution During the Terminal Elimination Phase Following Intravenous Administration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Vss; The Volume of Distribution at Steady State Following Intravenous Administration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: Vz/F; The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacokinetics (PK) of BVS857: CL/F; The Apparent Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Extravascular Administration</measure>
    <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypercatabolic Status Related to Severe Burn</condition>
  <arm_group>
    <arm_group_label>BVS857 Grp 1A open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.03 mg/kg of BVS857intravenously in open label manner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BVS857 Group 1B/1C, 2, 3, 4 Double Blind</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group 1B/1C, 2, 3, 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BVS857</intervention_name>
    <description>Group 1A&amp;1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.</description>
    <arm_group_label>BVS857 Grp 1A open label</arm_group_label>
    <arm_group_label>BVS857 Group 1B/1C, 2, 3, 4 Double Blind</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.</description>
    <arm_group_label>Placebo Group 1B/1C, 2, 3, 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burn injury comprising 2nd degree deep partial thickness and/or 3rd degree full
             thickness burns, â‰¥20% total body surface area with expected need for surgical
             intervention and not exceeding the sum of age plus burn size of 100 (Baux score)

          -  Dosing must occur within 8-12 days post-burn

          -  Subjects must weigh at least 45kgs (for group 1 with doses of 0.03mg/kg) and be under
             100 kg to participate in the study

        Exclusion Criteria:

          -  Spinal cord injury

          -  Hypoxic brain injury (Glasgow Coma Scale (GCS) &lt;8) at screening

          -  True conductive electric burn with suspected neurologic injury

          -  Uncontrolled diabetes with HbA1c &gt; 10% at screening, or known history of hypoglycemia,

          -  History of or active peripheral neuropathy or seizure disorder

          -  Systemic corticosteroids : &gt; 10mg/d of prednisone or equivalent, other investigational
             treatments (excluding investigational dressings), medications for weight loss
             including megestrol acetate, androgens or oral beta agonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>December 8, 2015</results_first_submitted>
  <results_first_submitted_qc>March 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2016</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn, Severe burn, Lean body mass, Cachexia, Hypermetabolism, Catabolism, Wound healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was planned to have 4 groups of patients. In Group 1: the bioavailability of BVS857 following subcutaneous administration was planned. Groups 2-4 (Group 4 optional) different BVS857 doses were planned for safety, PK and efficacy assessments. Study was terminated due to low enrollment as only 1 patient was enrolled</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BVS857 Grp 1A Open Label</title>
          <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group 1B/1C, 2, 3, 4</title>
        </group>
        <group group_id="P3">
          <title>BVS857 Group 1B/1C, 2, 3, 4 Double Blind</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BVS857 Grp 1A Open Label</title>
          <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Number of patients with adverse events as a measure of safety and tolerability</description>
        <time_frame>Over 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Number of patients with adverse events as a measure of safety and tolerability</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Measure by Change in Lean Body Mass (LBM)</title>
        <description>Total LBM is measured by dual energy X-ray absorptiometry (DXA) scan.</description>
        <time_frame>Groups 2,3&amp;4: Baseline, Day 35, Day 85 and Day 106</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Measure by Change in Lean Body Mass (LBM)</title>
          <description>Total LBM is measured by dual energy X-ray absorptiometry (DXA) scan.</description>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: Cmax; The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: Cmax; The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: Tmax; The Time to Reach the Maximum Concentration After Drug Administration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: Tmax; The Time to Reach the Maximum Concentration After Drug Administration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: AUClast; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: AUClast; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: AUCinf; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to Infinity</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: AUCinf; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to Infinity</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: T1/2; The Terminal Elimination Half-life</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:ay D1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: T1/2; The Terminal Elimination Half-life</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: CL; The Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Intravenous Administration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: CL; The Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Intravenous Administration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: Vz; The Volume of Distribution During the Terminal Elimination Phase Following Intravenous Administration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: Vz; The Volume of Distribution During the Terminal Elimination Phase Following Intravenous Administration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: Vss; The Volume of Distribution at Steady State Following Intravenous Administration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: Vss; The Volume of Distribution at Steady State Following Intravenous Administration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: Vz/F; The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: Vz/F; The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacokinetics (PK) of BVS857: CL/F; The Apparent Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Extravascular Administration</title>
        <time_frame>Groups 1: Day 1through to Day 56: Groups 2,3&amp;4:Day 1 through to Day 105</time_frame>
        <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
        <group_list>
          <group group_id="O1">
            <title>BVS857 Grp 1A Open Label</title>
            <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics (PK) of BVS857: CL/F; The Apparent Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Extravascular Administration</title>
          <population>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BVS857 Grp 1A Open Label</title>
          <description>0.03 mg/kg of BVS857 intravenously in open label manner followed by subsequent subcutaneous doses weekly at day 15,22 and 29.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

